Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ferdous Al-Faruque

Senior Reporter

Washington, DC
Ferdous Al-Faruque, known as Danny, specializes in reporting on new medical device technologies such as mobile health, combination products, unique device identifiers, and issues surrounding interoperability and cyber security. He is also our resident podcast expert, and has brought listeners the voices of top FDA officials as well as industry leaders. Danny is a big sci-fi fan, especially Battlestar Galactica and Star Trek. Qapla'!
Set Alert for Articles By Ferdous Al-Faruque

Latest From Ferdous Al-Faruque

mHealth Developer Works Around Traditional Reimbursement Barriers

Glooko says it has found more success by pitching its diabetes management app to self-insured employers and to payers as a tool they can implement to reduce spending, rather than by pursuing reimbursement in the traditional way. It's one model for the digital-health sector in the current health-care environment.

Digital Health Market Access

Theranos' Holmes, Balwani Slammed By SEC For 'Massive Fraud'

In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.

Enforcement Legal Issues

Device Week, March 9, 2018 – US Policy Updates: CMS, FTC, FDA, Supreme Court

On this week's podcast, we discuss US medtech policy developments from the Centers for Medicare and Medicaid Services, the Federal Trade Commission, FDA and the Supreme Court.

Policy Regulation

A Post-IPR World Would Hold Patent Risks And Benefits For Medtech Companies

The inter partes review process, which provides a non-court strategy for invalidating patents, could conceivably come to an end depending on the Supreme Court's ruling in a case this spring. Device firms have been wary of the IPR process, which can weaken patent protections, but attorneys point out that it has also been a helpful tool in fighting against the growing threat of patent trolls in medtech. While bets are for upholding the system, legal experts say device companies could fall back to other processes previously used to stop patent trolls.

Intellectual Property Legal Issues

Neuro Panel Takeaways: Detailed Responses On Aneurysm Devices From US FDA Advisors

Point-by-point clinical trial recommendations from US FDA's Neurological Devices Advisory Panel at a recent meeting on intracranial aneurysm devices.

Advisory Committees Neurology

US FDA Greenlights First Direct-To-Consumer Cancer-Risk Test

23andMe gained FDA go-ahead for the first direct-to-consumer genetic test for cancer risk, as the firm continues to map out regulatory frameworks for the DTC gene-screening space with its third de novo authorization in three years.

Approvals Regulation
See All